Small-cap spotlight

RAPID diagnostics firm Abingdon Health has been boosted by a contract from BioSure UK to manufacture its Covid-19 lateral flow tests. Abingdon’s AIM-quoted shares rose 9% or 3.5p to 44p after the signing of the exclusive agreement that makes use of its facilities at York and Doncaster. Shares have fallen back since hitting 126p in January and the 96p at which the company raised £22 million from institutional investors in December.